123 related articles for article (PubMed ID: 8522489)
1. Experimental therapies in the treatment of cutaneous T-cell lymphoma.
Foss FM; Kuzel TM
Hematol Oncol Clin North Am; 1995 Oct; 9(5):1127-37. PubMed ID: 8522489
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulators in the treatment of cutaneous lymphoma.
Rogalski C; Dummer R; Burg G
J Eur Acad Dermatol Venereol; 1999 Sep; 13(2):83-90. PubMed ID: 10568485
[TBL] [Abstract][Full Text] [Related]
3. Future perspectives in the treatment of cutaneous T-cell lymphoma (CTCL).
Dummer R
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S33-6. PubMed ID: 16516674
[TBL] [Abstract][Full Text] [Related]
4. Standard and experimental therapy in cutaneous T-cell lymphomas.
Dummer R; Cozzio A; Meier S; Beyeler M; Laetsch B; Doebbeling U; Urosevic M
J Cutan Pathol; 2006 Feb; 33 Suppl 1():52-7. PubMed ID: 16412213
[TBL] [Abstract][Full Text] [Related]
5. Choices in the treatment of cutaneous T-cell lymphoma.
Hymes KB
Oncology (Williston Park); 2007 Feb; 21(2 Suppl 1):18-23. PubMed ID: 17474355
[TBL] [Abstract][Full Text] [Related]
6. Novel treatment approaches for cutaneous T-cell lymphoma.
Foss FM; Kuzel TM
Cancer Treat Res; 1999; 99():227-40. PubMed ID: 9891869
[No Abstract] [Full Text] [Related]
7. Rational therapy for cutaneous T-cell lymphomas in the 1990s. Fact or fancy?
Bunn PA
Arch Dermatol; 1995 May; 131(5):603-5. PubMed ID: 7537952
[No Abstract] [Full Text] [Related]
8. Treatment of cutaneous T-cell lymphoma: an update.
Young JW
J Am Osteopath Assoc; 1993 May; 93(5):591-8, 603. PubMed ID: 8314721
[TBL] [Abstract][Full Text] [Related]
9. [Novel treatment modalities in cutaneous T cell lymphoma. Biologic response modifiers].
Marschalkó M
Orv Hetil; 2005 Jun; 146(23):1251-5. PubMed ID: 15988920
[TBL] [Abstract][Full Text] [Related]
10. Treatment of cutaneous T-cell lymphoma with retinoids.
Zhang C; Duvic M
Dermatol Ther; 2006; 19(5):264-71. PubMed ID: 17014481
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis.
Rook AH; Gottlieb SL; Wolfe JT; Vowels BR; Sood SS; Niu Z; Lessin SR; Fox FE
Clin Exp Immunol; 1997 Jan; 107 Suppl 1():16-20. PubMed ID: 9020930
[TBL] [Abstract][Full Text] [Related]
12. Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen.
Foon KA; Oseroff AR; Vaickus L; Greenberg SJ; Russell D; Bernstein Z; Pincus S; Köhler H; Seon BK; Tahaoglu E
Clin Cancer Res; 1995 Nov; 1(11):1285-94. PubMed ID: 9815923
[TBL] [Abstract][Full Text] [Related]
13. Emerging new therapies for cutaneous T-cell lymphoma.
Duvic M; Cather JC
Dermatol Clin; 2000 Jan; 18(1):147-56. PubMed ID: 10626120
[TBL] [Abstract][Full Text] [Related]
14. [Current therapy concepts in cutaneous T-cell lymphomas].
Nestle FO; Häffner AC; Schmid MH; Dummer R; Burg G
Schweiz Med Wochenschr; 1997 Feb; 127(8):311-20. PubMed ID: 9157537
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs in cutaneous T-cell lymphomas.
Dummer R
Expert Opin Emerg Drugs; 2005 May; 10(2):381-92. PubMed ID: 15934873
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous T-cell lymphomas: a review with emphasis on new treatment approaches.
Querfeld C; Rosen ST; Kuzel TM; Guitart J
Semin Cutan Med Surg; 2003 Sep; 22(3):150-61. PubMed ID: 14649582
[TBL] [Abstract][Full Text] [Related]
17. Use of biological response modifiers in the treatment of cutaneous T-cell lymphoma.
Rook AH; Yoo EK; Grossman DJ; Kao DM; Fox FE; Niu Z
Curr Opin Oncol; 1998 Mar; 10(2):170-4. PubMed ID: 9555542
[TBL] [Abstract][Full Text] [Related]
18. Staging and management of cutaneous T-cell lymphoma.
Scarisbrick JJ
Clin Exp Dermatol; 2006 Mar; 31(2):181-6. PubMed ID: 16487086
[TBL] [Abstract][Full Text] [Related]
19. [Biological dermatologic agents. The Danish Society of Dermatology].
Iversen L; Kragballe K;
Ugeskr Laeger; 2007 Mar; 169(12):1100. PubMed ID: 17394811
[No Abstract] [Full Text] [Related]
20. Novel multimodality biologic response modifier therapy, including bexarotene and long-wave ultraviolet A for a patient with refractory stage IVa cutaneous T-cell lymphoma.
Shapiro M; Rook AH; Lehrer MS; Junkins-Hopkins JM; French LE; Vittorio CC
J Am Acad Dermatol; 2002 Dec; 47(6):956-61. PubMed ID: 12451388
[No Abstract] [Full Text] [Related]
[Next] [New Search]
